We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
- Authors
Roze, S.; Saunders, R.; Brandt, A.‐S.; Portu, S.; Papo, N. L.; Jendle, J.
- Abstract
Aim To evaluate the clinical benefits and cost-effectiveness of the sensor-augmented pump compared with self-monitoring of plasma glucose plus continuous subcutaneous insulin infusion in people with Type 1 diabetes. Methods The CORE Diabetes Model was used to simulate disease progression in a cohort of people with baseline characteristics taken from a published meta-analysis. Direct and indirect costs for 2010-2011 were calculated from a societal payer perspective, with cost-effectiveness calculated over the patient's lifetime. Discount rates of 3% per annum were applied to the costs and the clinical outcomes. Results Use of the sensor-augmented pump was associated with an increase in mean discounted, quality-adjusted life expectancy of 0.76 quality-adjusted life years compared with continuous subcutaneous insulin infusion (13.05 ± 0.12 quality-adjusted life years vs 12.29 ± 0.12 quality-adjusted life years, respectively). Undiscounted life expectancy increased by 1.03 years for the sensor-augmented pump compared with continuous subcutaneous insulin infusion. In addition, the onset of complications was delayed (by a mean of 1.15 years) with use of the sensor-augmented pump. This analysis resulted in an incremental cost-effectiveness ratio of 367,571 SEK per quality-adjusted life year gained with the sensor-augmented pump. The additional treatment costs related to the use of the sensor-augmented pump were partially offset by the savings attributable to the reduction in diabetes-related complications and the lower frequency of self-monitoring of plasma glucose. Conclusions Analysis using the CORE Diabetes Model showed that improvements in glycaemic control associated with sensor-augmented pump use led to a reduced incidence of diabetes-related complications and a longer life expectancy. Use of the sensor-augmented pump was associated with an incremental cost-effectiveness ratio of 367,571 SEK per quality-adjusted life year gained, which is likely to represent good value for money in the treatment of Type 1 diabetes in Sweden.
- Subjects
SWEDEN; BLOOD sugar monitoring; HYPOGLYCEMIA; COST effectiveness; PEOPLE with diabetes; ECONOMICS; FEAR; HEALTH; LIFE expectancy; MEDICAL care; TYPE 1 diabetes; EVALUATION of medical care; MEDICAL care costs; MEDICAL technology; PATIENTS; WEARABLE technology; DATA analysis; DESCRIPTIVE statistics; DISEASE complications; PSYCHOLOGY; DIAGNOSIS; PREVENTION
- Publication
Diabetic Medicine, 2015, Vol 32, Issue 5, p618
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.12661